T
Thomas C. Merigan
Researcher at Stanford University
Publications - 515
Citations - 34283
Thomas C. Merigan is an academic researcher from Stanford University. The author has contributed to research in topics: Interferon & Virus. The author has an hindex of 98, co-authored 514 publications receiving 33941 citations. Previous affiliations of Thomas C. Merigan include University of Arizona & Rockefeller Institute of Government.
Papers
More filters
Journal ArticleDOI
Cytomegalovirus retinitis in immunosuppressed hosts. I. Natural history and effects of treatment with adenine arabinoside.
TL;DR: Adenine arabinoside may have some beneficial effect on selected patients with progressive CMV retinitis and administration was associated with significant gastrointestinal, hematologic, and neurologic side effects.
Journal ArticleDOI
Induction of Circulating Interferon by Synthetic Anionic Polymers of Known Composition
TL;DR: This communication confirms the findings, characterizes this antiviral activity appearing in sera of mice injected with synthetic anionic copolymers of defined composition, identifies it as interferon, and explores certain of the structural requirements forCopolymers to act as Interferon inducers.
Journal ArticleDOI
Short-Term Safety and Antiretroviral Activity of T-1249, a Second-Generation Fusion Inhibitor of HIV
Joseph J. Eron,Roy M. Gulick,John Bartlett,Thomas C. Merigan,Roberto C. Arduino,J. Michael Kilby,Bienvenido G. Yangco,Adriann Diers,Claude Drobnes,Ralph DeMasi,Michael E. Greenberg,Thomas E. Melby,Claire Raskino,Pam Rusnak,Ying Zhang,Rebecca Spence,G. Diego Miralles +16 more
TL;DR: Results indicate that T-1249 is a potent new therapeutic agent for HIV-1 infection and no dose-limiting toxicity was identified.
Journal ArticleDOI
Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma.
Arthur C. Louie,James G. Gallagher,Karol Sikora,Ronald Levy,Saul A. Rosenberg,Thomas C. Merigan +5 more
TL;DR: Interferon has activity against non-Hodgkin's lymphoma, and prior treatment with chemotherapy does not preclude a response to interferon.
Journal ArticleDOI
Antiviral Activity of Lamivudine in Salvage Therapy for Multidrug-Resistant HIV-1 Infection
Thomas B. Campbell,Nancy S. Shulman,Steven C. Johnson,Andrew R. Zolopa,Russell K. Young,Lane Bushman,Courtney V. Fletcher,E. Randall Lanier,Thomas C. Merigan,Daniel R. Kuritzkes +9 more
TL;DR: In select cases of multidrug-resistant HIV-1 infection, lamivudine contributes to suppression of HIV- 1 replication, despite the presence of M184V mutations and lamivUDine resistance.